It focuses on the treatment of hematologic malignancies or blood cancers.
Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers.
Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development.
Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 19, 2002 | Series B | $27.50M | 2 | — | — | Detail |
Jan 1, 2001 | Series A | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Biofrontier Partners | — | Series B |
Versant Ventures | — | Series B |